Delivery Order SPE2DB24D2101-SPE2DB25FKKCL

Award Date 5/1/25
Potential Completion Date 5/2/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,385.64 firm-fixed-price contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,932.90 firm fixed-price award is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a period of performance through February 25, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $8,064.10, is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a period of performance through April 9, 2025 and is a firm fixed-price, non-set-aside award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a $15,737.88 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the purchase of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication. The award has an ultimate completion date of January 23, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,929.20 firm fixed-price contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of February 18, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a $2,819.97 delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of January 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,461.44, is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract is a firm fixed-price delivery order with an ultimate completion date of April 17, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,559.76 firm fixed-price contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has an ultimate completion date of February 25, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a $15,170.10 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL, a medication used to treat diabetes. The award has an ultimate completion date of June 11, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $26,753.76, is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside...
  • SPE2DB24D2101
    Indefinite Delivery Contract
  • SPE2DB24D2101-SPE2DB25FKKCL
    Delivery Order

This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $12,948.16 firm-fixed-price contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication. The contract has an ultimate completion date of May 2, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is not set aside and is part of the company's broader federal contract work supporting military and veteran healthcare systems.

Generated 7/31/25, 10:31 AM